Editorial Cardiovascular & Renal: Ischaemic preconditioning: rational basis for drug design

References

• REIMER K, MURRY C, YAMASAWA I, HILL M, JENNINGS R:Four brief periods of ischaemia cause no cumulative ATP loss or necrosis. Am. J. Physiol. (1986) 251:H1306–H1315.
   PubMed Web of Science ®Google Scholar
• MLTRRY C, JENNINGS R, REIMER K: Preconditioning withischaemia: a delay of lethal cell injury in ischaemic myocardiuna. Circulation (1986) 74:1124–1136.
   PubMedGoogle Scholar
• BAXTER G, GOMA F, YELLON D: Duration of the 'second window of protection' following ischaemic precondi-tioning in the rabbit J. Mol. Cell. Cardiol. (1995) 27:A162.
   Google Scholar
• BELLARDINELLI L, LINDEN J, BERNE R: The cardiac effects of adenosine. Cardiovasc. Dis. (1989) 32:73–97.
   Google Scholar
• STILES G: Adenosine receptors: physiological regula- STILES G: Adenosine receptors: physiological regula-tion and biochemical mechanisms. News Physiol. Sci. (1991) 6:161–164.
   Google Scholar
• VAN \VYLEN D, WILLIS J, SODHI J et al.: Cardiac micro-dialysis to estimate interstitial adenosine and coronary blood flow. Am. J. Physiol. (1990) 258:H1642–H1649.
   Google Scholar
• ELY S, MENTZER R, LASLEY R, LEE B, BERNE R: Functionaland metabolic evidence of enhanced myocardial toler-ance to ischaemia and reperfusion with adenosine. J. 7borac. Cardiovasc. Surg. (1985) 90:549–556.
   Web of Science ®Google Scholar
• LIU G, THORNTON J, VAN WINKLE D et al.. Protectionagainst infarction afforded by preconditioning is medi-ated by Al adenosine receptors in rabbit heart. Circula-tion (1991) 84(1):350–356.
   Google Scholar
• DOWNEY JM, LIU GS, THORNTON JD: Adenosine and theanti-infarct effects of preconditioning. Cardiovasc. Res. (1993) 27(1):3–8.
   PubMed Web of Science ®Google Scholar
• TSUCHIDA A, MIURA T, MIKI T, SHIMAMOTO K, IIMURA0: Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning. Cardiovasc. Res. (1992) 26(5)456–461.
   Google Scholar
• VAN BELLE H: Nucleoside transport inhibition: a thera-peutic approach to cardioprotection via adenosine? Cardiovasc. Res. (1993) 27(1):68–76.
   Google Scholar
• MULLANE K: Acadesine: the prototype adenosine regu-lating agent for reducing myocardial ischaemic injury. Cardiovasc. Res. (1993) 27(1):43–47.
   PubMed Web of Science ®Google Scholar
• TSUCHIDA A, THOMPSON R, OLSSON RA, DOWNEY JM: The anti-infarct effect of an adenosine Ai-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart. J. Mol. Cell Cardiol. (1994) 26(3):303–311.
   PubMed Web of Science ®Google Scholar
• VEGH A, SZEKERES L, PARRATT J: Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway. Br.J. Pharmacol. (1992) 107(3):648–652.
   PubMed Web of Science ®Google Scholar
• VEGH A, PAPP J, SZEKERES L, PARRATT J: The local intracoronary administration of methylene blue pre-vents the pronounced antiarrhythmic effect of ischae-mic preconditioning. Br. J. Pharmacol. (1992) 107(4):910–911.
   PubMed Web of Science ®Google Scholar
• PARRATT J: Endogenous myocardial protective (antiar-rhythmic) substances. Cardiovasc. Res. (1993) 27:693–702.
   PubMed Web of Science ®Google Scholar
• WAINWRIGHT C, PARRAT J, VAN BELLE H: The antiar-rhythmic effects of the nucleoside transporter inhibi-tor, R75231, in anaesthetised pigs. Br. J. Pharmacol. (1993) 109:592–599.
   PubMed Web of Science ®Google Scholar
• ITOYA M, MIURA T, URABE K, ISHIMOTO R, IIMURA 0: Nucleoside transport inhibitors enhance the infarct size limiting effect of preconditioning. Circulation (1992) 86(Suppl.):125.
   Google Scholar
• PARRATT J: Cardioprotection by angiotensin converting enzyme inhibitors - the experimental evidence. Cardiovasc. Res. (1994) 28:183–189.
   PubMed Web of Science ®Google Scholar
• THORNTON J, LIU G, DOWNEY J: Pretreatment withpertussis toxin blocks the protective effects of precon-ditioning: evidence for a G-protein mechanism. J. Mot. Cell. Cardiol. (1993) 25(3):311–320.
   PubMed Web of Science ®Google Scholar
• PIACENTINI L, WAINWRIGHT C, PARRATT J: The antiar-rhythmic effect of ischaemic preconditioning in iso-lated rat heart involves a pertussis toxin sensitive mechanism. Cardiovasc. Res. (1993) 27(4):674–680.
   PubMed Web of Science ®Google Scholar
• LAWSON C, COLTART D, HEARSE D: The antiarrhythrnic action of ischaemic preconditioning in rat hearts does not involve functional G; proteins. Cardiovasc. Res. (1993) 27(4):681–687.
   PubMed Web of Science ®Google Scholar
• LIU Y, DOWNEY J: Preconditioning against infarction in the rat heart does not involve a pertussis toxin sensitive G protein. Cardiovasc. Res. (1993) 27(4):608–611.
   PubMed Web of Science ®Google Scholar
• FLEMING J, WISLER P, WATANABE A: Signal transduction by G proteins in cardiac tissues. Circulation (1992) 85:419–433.
   Google Scholar
• YTREHUS K, LIU Y, DOWNEY J: Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am. J. Physiol. (1994) 266:H1145–H1152.
   PubMed Web of Science ®Google Scholar
• SPEECHLY-DICK M, MOCANU M, YELLON D: Protein ki-nase C. Its role in ischemic preconditioning in the rat. Circ. Res. (1994) 75(3):586–590.
   Google Scholar
• PRZYKLENK K, SUSSMAN MA, SIMKHOVICH BZ, KLONER RA: Does ischemic preconditioning trigger transloca- tion of protein kinase C in the canine model? Circula-tion (1995) 92(6):1546–1557.
   PubMed Web of Science ®Google Scholar
• VALHAUS C, SCHULZ R, POST H, ONALLAH R, HEUSCH G: No prevention of ischaemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ. Res. (1996) 79:407–414.
   PubMed Web of Science ®Google Scholar
• VOGT A, HTUN P, ARRAS M, PODZUWEIT T, SCHAPER W: Intramyocardial infusion of tool drugs for the study of molecular mechanisms in ischaemic preconditioning. Basic Res. Cardiol. (1996) 91:389–400.
   PubMed Web of Science ®Google Scholar
• LIU Y, YTREHUS K, DOWNEY J: Evidence that transloca-don of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J. Mot. Cell Cardiol. (1994) 26(5):661–668.
   PubMed Web of Science ®Google Scholar
• MITCHELL MB, MENG X, AO L et al.: Preconditioning ofIsolated rat heart is mediated by protein kinase C. Circ. Res. (1995) 76(1):73–81.
   PubMed Web of Science ®Google Scholar
• BOGOYEVITCH M, PARKER P, SUGDEN P: Charac-terization of protein kinase C expression in adult rat heart. Circ. Res. (1993) 72:757–767.
   PubMedGoogle Scholar
• IKEDA U, ARISAKA H, TAKAYASU T et al.: Protein kinase C activation aggravates hypoxic 'myocardial injury by stimulation of NaVIr exchange. J. Mol. Cell Cardiol. (1988) 20:493–500.
   PubMed Web of Science ®Google Scholar
• BLACK S, PHAGBEM1 S, CHI L, FRIEDRICHS S, LUCCHESIB: Phorbol-ester induced ventricular fibrillation in the Langendorff-perfused rabbit heart: antagonism by staurosporine and glibenciamide. J. Mol. Cell Cardiol. (1993) 25:1427–1438.
   PubMed Web of Science ®Google Scholar
• PARRATT JR: Protection of the heart by ischaemic pre-conditioning: mechanisms and possibilities for phar-macological exploitation. Trends Pharmacol. Sci. (1994) 15(1):19–25.
   PubMedGoogle Scholar
• SZEKERES L, PATARICZA J, SZILVASSY Z, UDVARY E. VEGI I A: Cardioprotection: endogenous protective mecha-nisms promoted by prostacyclin. Basic Res. Cardiol. (1992) 87:215–221.
   PubMedGoogle Scholar
• GROSS G, AUCHAMPACH J: Blockade of ATP-sensitive potassium channels prevents myocardial precondi-tioning in dogs. Circ. Res. (1992) 70(2):223–233.
   PubMed Web of Science ®Google Scholar
• AUCHAMPACH J, GROVER G, GROSS G: Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hy-droxydecanoate. Cardiovasc. Res. (1992) 26(11)1054–1062.
   Google Scholar
• THORNTON J, THORNTON C, STERLING D, DOWNEY J: Blockade of ATP-sensitive potassium channels in-creases infarct size but does not prevent precondition-ing in rabbit hearts. Circ. Res. (1993) 72(1):44–49.
   PubMed Web of Science ®Google Scholar
• YAO Z, GROSS G: Effects of ICATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation (1994) 89:1769–1775.
   PubMed Web of Science ®Google Scholar
• THEROUX P, QUIMET H, MCCANS J et al.: Aspirin, hepa-rin, or both to treat unstable angina. New Engl. J. Med. (1988) 319:1105–1111.
   PubMed Web of Science ®Google Scholar
• OPIE L: Cardiac metabolism - emergence, decline, andresurgence. Part 2. Cardiovasc. Res. (1992) 26:817–830.
   PubMed Web of Science ®Google Scholar
• KATUS H, SCHOEPPENTHAU M, TANZEEM A et al.: Non-invasive assessment of perioperative myocardial cell damage by circulating cardiac Troponin-T. Br. Heart J. (1991) 65:259–264.
   PubMedGoogle Scholar
• MALR J, WIESER C, SEIBT I et al.: Troponin-T to diagnose myocardial infarction in bypass surgery [Letter]. Lancet (1991) 337:434–435.
   Web of Science ®Google Scholar
• HAKE U, SCHMID F, IVERSEN S et al.: Troponin-T - a reliable marker of perioperative myocardial infarction? Eur.J. Cardiothorac. Surg. (1993) 7:628–633.
   Web of Science ®Google Scholar